France
HalioDx is a global diagnostics company that focuses on improving patient care through its immuno-oncology diagnostic technologies and services. Formerly known as HalioDx, the company operates in the Health Care and Pharmaceutical sectors and is headquartered in France. One of their flagship offerings, the Immunoscore® assay, has been developed from Dr. Jérôme Galon's pioneering research and is a CLIA or CE-marked test for colon cancer. This technology provides crucial insights into a tumor's immunological contexture, aiding oncologists in making daily treatment decisions for cancer patients.
In 2018, HalioDx secured an €18.50M Series B investment from a group of investors, including BNP Paribas Developpement, Quest for Growth, Sofipaca, PSIM fund, Sham, and MI Care. This extensive financial backing underscores the growing importance and potential of their diagnostic technologies in the era of immuno-oncology and combination therapies.
By facilitating informed diagnoses and treatment decisions, especially in the field of immuno-oncology, HalioDx's technologies contribute to the advancement of precision medicine. The company's focus on leveraging the immune response to tumors as a key indicator of disease progression suggests potential applications beyond colon cancer, opening doors for broader diagnostic capabilities.
